Mark C. McKenna - 07 Jan 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Director
Signature
/s/ Louise Kooij by Power of Attorney from Mark C. McKenna
Issuer symbol
NAMS
Transactions as of
07 Jan 2026
Net transactions value
$0
Form type
4
Filing time
09 Jan 2026, 19:33:22 UTC
Previous filing
11 Aug 2025
Next filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McKenna Mark C. Director C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Louise Kooij by Power of Attorney from Mark C. McKenna 09 Jan 2026 0001749623

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Award +3,400 +49% 10,360 07 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +15,300 $0.000000 15,300 07 Jan 2026 Ordinary Shares 15,300 $35.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2 Each RSU was granted on January 7, 2026 for no consideration.
F3 All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date.